Senate HELP Chairman Bernie Sanders launches another salvo in drug pricing war, this one aimed at popular weight loss drugs.

Coverage for its long-acting insulin, Levamir, dropped from 90% to about 35% when the company dropped its list price by 65%.

The PBMs say out-of-pocket insulin costs have fallen sharply since 2019. The Pharmaceutical Care Management Association, ...

Leading pharmacy benefit managers are reportedly willing to expand coverage for Novo Nordisk’s (NVO) popular diabetes and ...

California lawmakers have sent a bill to Gov. Gavin Newsom that aims to rein in the PBMs they say drive up costs and limit ...

The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...

When government officials and politicians scrutinize high U.S. drug prices, the role of insurers and pharmacy benefit ...

Ted Okon, MBA, executive director of the Community Oncology Alliance, spoke with The American Journal of Managed Care® about how the Federal Trade Commission's (FTC) lawsuit against pharmacy benefit ...

WASHINGTON — Senate health committee chair Bernie Sanders said major drug middlemen have agreed not to limit coverage of Novo ...

The government’s antitrust watchdog on Friday sued three massive health conglomerates, accusing their drug middlemen of ...

Novo Nordisk's CEO faced lawmakers in a grueling 2.5-hour hearing to discuss the cost of blockbuster drugs Ozempic and Wegovy ...

The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...